Viridian Therapeutic (VRDN) Reiterated at Market Outperform by Citizens: Lumvoa Approved
Tweet Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $35.00 price target on Viridian Therapeutic (NASDAQ: VRDN).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
